Adult urologySymptom assessment tool for overactive bladder syndrome—overactive bladder symptom score
Section snippets
OABSS Development
Using the definition of the OAB syndrome,1 we selected four symptoms—daytime frequency, nighttime frequency, urgency, and urgency incontinence—for the symptom questionnaire. The weighing of the symptom scores was done using a secondary analysis of an epidemiologic survey on lower urinary tract symptoms (LUTS) that involved 4570 Japanese residents older than 40 years of age.6 In the survey, the actual number of voiding frequencies was recorded; urgency and urgency incontinence events were rated
OABSS Development
The relation between symptom frequency and influence rate is displayed in Figure 1. The influence rate of daytime frequency was generally low (20% at most). The influence rate of nighttime frequency increased steadily up to about 30% at three times a night and stabilized thereafter. In contrast, the influence rate of urgency and urgency incontinence increased throughout the full range of symptom frequency, reaching the maximal influence rate of greater than 50%. Thus, we assumed the relative
Comment
OAB is a symptom syndrome with urinary urgency, urinary frequency, and urgency incontinence.1 To collectively express these OAB symptoms in a single score, we developed the OABSS in this study. The score is obtained as the simple sum of four symptom scores, which address daytime voiding, nighttime voiding, urgency, and urgency incontinence. The relative weight among the four scores was determined on the basis of the maximal influence rate of the symptom in the epidemiologic survey.6 Some
Conclusions
A symptom assessment tool for OAB syndrome, the OABSS, has been developed and validated. The OABSS integrates four symptoms into a single score and may be a useful tool for research and clinical practice. Additional studies using the OABSS as a symptom assessment tool are warranted.
References (22)
- et al.
Definition and epidemiology of overactive bladder
Urology
(2002) - et al.
Current and future pharmacological treatment for overactive bladder
J Urol
(2002) - et al.
A validated patient reported measure of urinary urgency severity in overactive bladder for use in clinical trials
J Urol
(2005) - et al.
The Overactive Bladder-Symptom Composite Scorea composite symptom score of toilet voids, urgency severity and urge urinary incontinence in patients with overactive bladder
J Urol
(2005) - et al.
The American Urological Association symptom index for benign prostatic hyperplasia
J Urol
(1992) - et al.
The standardisation of terminology of lower urinary tract functionreport from the Standardisation Sub-Committee of the International Continence Society
Neurourol Urodyn
(2002) - et al.
Overactive bladder significantly affects quality of life
Am J Manag Care
(2000) - et al.
Psychometric validation of an overactive bladder symptom and health-related quality of life questionnairethe OAB-q
Qual Life Res
(2002) - et al.
Health-related quality of life of Japanese patients with overactive bladder treated with extended-release tolterodine or immediate-release oxybutynina randomized, placebo-controlled trial
World J Urol
(2004) - et al.
Epidemiologic survey on lower urinary tract symptoms in Japan
J Neurogen Bladder Soc
(2003)
Test-retest reliability of four questionnaires for patients with overactive bladderthe Overactive Bladder Questionnaire (OAB-q), Patient Perception of Bladder Condition (PPBC), Urgency Questionnaire (UQ), and the Primary OAB Symptom Questionnaire (POSQ)
Neurourol Urodyn
Cited by (573)
Prevalence of overactive bladder among overweight and obese women: A prospective cross-sectional cohort study
2024, European Journal of Obstetrics and Gynecology and Reproductive BiologyPredictive patterns of lower urinary tract symptoms and bacteriuria in adults with type 2 diabetes
2024, Diabetology International